Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).

Key facts

Study ID

NCT00268970

Run by

Agennix

People needed

40

Starts

2005-12-01

Expected to finish

2009-09-01

Last updated by the study team

2012-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed advanced NSCLC
• Patients must not have received any prior antineoplastic chemotherapy or investigational product for lung cancer prior to study entry.
• Patients must have at least one unidimensionally measurable lesion definable by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
• ECOG performance status of ≤ 2.

Where it is running

• Sarah Cannon Research Institute — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.